Dossier assessment
Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy
Added benefit not proven
Project details
- Project no.
- A23-36
- Commission
- Commission awarded on 24.04.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed